Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma

Rosa Nguyen, Anand G. Patel, Lyra M. Griffiths, Jason Dapper, Elizabeth A. Stewart, Jim Houston, Melissa Johnson, Walter J. Akers, Wayne L. Furman, Michael A. Dyer

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Faithful tumor mouse models are fundamental research tools to advance the field of immuno-oncology (IO). This is particularly relevant in diseases with low incidence, as in the case of pediatric malignancies, that rely on pre-clinical therapeutic development. However, conventional syngeneic and genetically engineered mouse models fail to recapitulate the tumor heterogeneity and microenvironmental complexity of human pathology that are essential determinants of cancer-directed immunity. Here, we characterize a novel mouse model that supports human natural killer (NK) cell development and engraftment of neuroblastoma orthotopic patient-derived xenograft (O-PDX) for pre-clinical antibody and cytokine testing. Using cytotoxicity assays, single-cell RNA-sequencing, and multi-color flow cytometry, we demonstrate that NK cells that develop in the humanized mice are fully licensed to execute NK cell cytotoxicity, permit human tumor engraftment, but can be therapeutically redirected to induce antibody-dependent cell-mediated cytotoxicity (ADCC). Although these cells share phenotypic and molecular features with healthy controls, we noted that they lacked an NK cell subset, termed activated NK cells, that is characterized by differentially expressed genes that are induced by cytokine activation. Because this subset of genes is also downregulated in patients with neuroblastoma compared to healthy controls, we hypothesize that this finding could be due to tumor-mediated suppressive effects. Thus, despite its technical complexity, this humanized patient-derived xenograft mouse model could serve as a faithful system for future testing of IO applications and studies of underlying immunologic processes.

Original languageEnglish (US)
Pages (from-to)721-732
Number of pages12
JournalCancer Immunology, Immunotherapy
Issue number3
StatePublished - Mar 2021
Externally publishedYes


  • Antibody therapy
  • Natural killer cells
  • Neuroblastoma
  • Pediatric oncology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma'. Together they form a unique fingerprint.

Cite this